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ABSTRACT
Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in
Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been
proven to reduce symptoms associated with SAR. We investigated the safety and efficacy of omalizumab in the
treatment of patients with Japanese cedar pollen-induced SAR compared to placebo.
Methods: A randomized, placebo-controlled, double-blind study was conducted in 100 Japanese patients with
a history of moderate-to-severe SAR induced by Japanese cedar pollens. Omalizumab (150, 225, 300, or 375
mg ) or placebo was administered subcutaneously every 2 or 4 weeks based on serum total IgE and body
weight at baseline. The primary efficacy variable was the mean of daily nasal symptom medication scores (sum
of the daily nasal symptom severity score and daily nasal rescue medication score) during the treatment period.
Secondary efficacy variables included the daily ocular symptom medication score and related variables.
Results: Primary and all secondary efficacy variable scores were significantly lower in the omalizumab group
than in the placebo group ( P < .01). Serum free IgE levels markedly decreased in the omalizumab group and
were associated with clinical efficacy. The overall incidence of injection site reactions was higher in the omali-
zumab group than in the placebo group; however, the adverse reaction profile was similar between the two
groups when excluding injection site reactions. No anti-omalizumab antibodies were detected.
Conclusions: Omalizumab was effective and safe in the treatment of SAR induced by Japanese cedar pol-
len.
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INTRODUCTION
Allergic rhinitis , especially Japanese cedar pollen-
induced seasonal allergic rhinitis (SAR), is a highly
prevalent disease in Japan.1-3 Twelve percent of the
total land in Japan is covered by Japanese cedar. Ap-
proximately 20 million people in Japan, who account
for about 17% of the population, experience this form
of SAR . 3 During the pollen season ( February to
April), the majority of these patients undergo treat-
ment, i.e., pharmacotherapy with antihistamines and
corticosteroids, specific immunotherapy, folk medi-
cine , and protective measures , such as masks ,
glasses, caps, and coats, to reduce pollen inhalation
or their adhesion to the body.1 The total direct cost of
medical treatments for Japanese cedar pollen-induced
SAR is estimated to be at least 120 billion yen ($1 bil-
lion dollars) annually.4 Furthermore, daily activities
and quality of life are reduced during the pollen sea-
son due to rhinoconjunctival symptoms or pharma-
cological side-effects.5 Thus, SAR induced by Japa-
nese cedar pollen is a substantial social problem in Ja-
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Omalizumab, a recombinant humanized monoclo-
nal anti-IgE antibody, which binds to the serum free
IgE molecule and forms small biologically inert com-
plexes, blocks the interaction between IgE and effec-
tor cells which trigger the allergic response irrespec-
tive of allergen type.6,7 Circulating free IgE can be re-
duced up to 99% with omalizumab,8 thus suppressing
the activation of effector cells (e.g., mast cells). Fur-
thermore , an omalizumab-induced reduction in
serum-free IgE levels eventually down-regulates
FcεRI expression on basophils 8 and mast cells . 9
Down-regulation of the receptor reduces the availabil-
ity of receptor sites for cross-linking of IgE. Based on
this mechanism of action, omalizumab is expected to
be effective for type I allergic diseases mediated by
allergen-specific IgE antibodies.10,11 Indeed, omalizu-
mab has already been shown to be effective for birch-
and ragweed-induced SAR, perennial allergic rhinitis
(PAR), and allergic asthma,12-19 and is now approved
for the treatment of allergic asthma in the United
States and Europe.
To investigate the safety and efficacy of omalizu-
mab and to examine the appropriateness of its dose
in Japanese patients with SAR, we conducted a ran-
domized , placebo-controlled , double-blind study in
Japanese patients with moderate-to-severe Japanese
cedar pollen-induced SAR. This was the first clinical
trial to treat Japanese SAR patients with omalizumab.
On the basis of previous oversea studies , the dose
and regimen which we employed in the present study
were expected to reduce serumfree IgE levels to be-
low 50 ngmL, a level which is considered important
to gain optimal efficacy.20
METHODS
STUDY SUBJECTS
Patients who met the following criteria were consid-
ered eligible for enrollment: age (20 to 64 years); a
history of SAR induced by Japanese cedar pollen in at
least 2 consecutive years; presentation of at least 4 of
8 moderate-to-severe symptoms ( sneezing , itchy
nose , runny nose , stuffy nose , itchy eyes , watery
eyes, red eyes, and itchy throat), which persisted for
one or more weeks during the last Japanese cedar
pollen season; presence of IgE specific to Japanese
cedar pollens (CAP-RAST: 2+) at baseline; serum
total IgE levels of 30 to 700 IUmL and body weights
of 30 to 150 kg at baseline; and no symptoms of aller-
gic rhinitis at 1 month prior to the onset of the
screening period.
Patients who had a history of the following were
excluded from the study: specific immunotherapy to
Japanese cedar pollen in the previous 2 years; severe
anaphylactoid or anaphylactic reactions; active or re-
cent development (within 3 months) of any other type
of rhinitis; positive reaction to omalizumab at screen-
ing; pregnantnursing women; and serious medical
conditions.
The present study was conducted in compliance
with the current good clinical practice, and the proto-
col was approved by each institutional ethical com-
mittee . Prior to the onset of the study, written in-
formed consent was obtained from all the patients
who were enrolled.
STUDY DESIGN
This randomized , placebo-controlled , double-blind
study was conducted in two regions of Japan (Tokyo
and Osaka) between October 2001 and April 2002
and consisted of a 4-week screening period , a 12-
week treatment period, and a 12-week follow-up pe-
riod after final dosing. Following screening, eligible
patients were assigned to receive omalizumab or pla-
cebo at a 1 : 1 ratio.
The start day of the Japanese cedar pollen scatter-
ing period was defined as the first of 2 consecutive
days when1 graincm2 were counted; the final day
of the pollen season was the first of 3 consecutive
days when no grain was counted. The peak Japanese
cedar pollen scattering period was defined as the
span between the first and last days when 30
grainscm2 were counted.
DOSES AND ADMINISTRATION
Omalizumab (150, 225, 300, or 375 mg) or placebo
was administered to patients subcutaneously every 2
or 4 weeks based on their serum total IgE level and
body weight at baseline. The initial dose was adminis-
tered at least at 1 month prior to the expected start-
ing date of the Japanese cedar pollen scattering pe-
riod. Omalizumab or placebo was administered to pa-
tients 3 or 6 times in total during the 12-week treat-
ment period.
The following drugs were permitted as rescue
medications: for nasal use [clemastine fumarate (tab-
let), sodium cromoglycate (nose drop), naphazoline
nitrate (nose drop)] and for ocular use [sodium cro-
moglycate (eye drop)]. Concomitant use of agents
were prohibited except for rescue medications. Spe-
cific immunotherapy was prohibited.
EVALUATION OF EFFICACY
Patients enrolled were requested to fill in the patient
diary in order to describe their seven rhinoconjuncti-
val symptoms (sneezing , itchy nose , runny nose ,
stuffy nose, itchy eyes, watery eyes, and red eyes) ac-
cording to the 4-point scale (0: none, 1: mild, 2: mod-
erate, and 3: severe) and to document rescue medica-
tion use, if any. Regarding each rescue medication,
its usage was scored 1 point regardless of dose and
frequency.
The primary efficacy variable was the mean of daily
nasal symptom medication scores (DNSMS) during
the treatment period . DNSMS (0―15 points ) con-
sisted of the sum of the daily nasal symptom severity
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score (DNSS)(0―12 points) and the daily nasal rescue
medication score (0―3 points).
Secondary efficacy variables included the daily ocu-
lar symptom medication score ( DOSMS ) ( 0 ― 10
points) [sum of the daily ocular symptom severity
score (DOSS)(0―9 points) and daily ocular rescue
medication score (0―1 point)]; DNSS; the daily nasal
rescue medication score; DOSS; the daily ocular res-
cue medication score ; the consumption per day of
rescue medications ; and the proportion of days in
which any rescue medication was taken.
ESTIMATION OF SERUM FREE IgE LEVELS
To investigate the relationship between serum IgE
level and efficacy of omalizumab, serum free IgE lev-
els were measured before dosing and at 4 and 12
weeks of the treatment period.12
EVALUATION OF SAFETY
Adverse events were examined throughout the treat-
ment period. Laboratory tests and check-up of vital
signs were conducted during the screening period
and at 4 and 12 weeks of the treatment period.
During the screening period and at 12 weeks after
final dosing , anti-omalizumab antibodies ( IgG iso-
type) were measured using two solid-phase ELISA
methods: one assay was to detect anti-omalizumab
Fab responses ; and another was to detect anti-
omalizumab Fc responses.12
STATISTICAL ANALYSIS
One hundred patients, assigned to the omalizumab
group and the placebo group at a 1 : 1 ratio, were re-
quired to detect a 0.30-point difference in the mean
DNSMS between treatment groups. This calculation
assumed 90% power at a significance level of 0.05, 2-
sided, and at a standard deviation of 0.50 for the dif-
ference.
Regarding efficacy, the following hypothesis tests
were used to examine study group comparability with
respect to demographic and baseline characteristics:
Fisher’s exact test for gender ; and Wilcoxon rank
sum test for age, history of Japanese cedar pollen-
induced SAR, IgE specific to Japanese cedar pollens,
and serum total IgE at baseline.
The full analysis set was used to analyze the pri-
mary variable ( i .e. , the mean DNSMS during the
treatment period) and to analyze the mean DNSMS
during the Japanese cedar pollen scattering period
and the peak Japanese cedar pollen scattering period.
These comparisons were based on the null hypothe-
sis that there is no difference between the study
groups. The mean DNSMS was analyzed using an
ANCOVA model which included study group, loca-
tion, and administration interval (2- or 4-week inter-
val). The least-squares mean (LSM) for each group
and the difference in LSM between the study groups
were determined. The mean DOSMS, each of symp-
tom severity scores, and each of rescue medication
scores were also analyzed similarly to the analysis of
the mean DNSMS.
The safety and tolerability of the study drugs are
summarized by appropriate descriptive methods.
RESULTS
PATIENT CHARACTERISTICS
Ninety-eight of 100 randomized subjects received
either of the study drugs: 48 received omalizumab
(50 randomized) and 50 received placebo. The re-
maining two subjects in the omalizumab group with-
drew during the screening period due to personal
reasons. No significant difference was found between
the omalizumab group and the placebo group with re-
spect to patient characteristics ( Table 1 ).
The Japanese cedar pollen scattering period
started at the beginning of February and finished at
the end of April (Fig. 1). All subjects received the first
administration at least at 1 month prior to the starting
date of the Japanese cedar pollen scattering period.
Five subjects (three receiving omalizumab and two
receiving placebo ) discontinued the study prema-
turely; among them, three (two receiving omalizu-
mab and one receiving placebo) ceased the study due
to adverse events.
EFFICACY
Daily Nasal Symptom Medication Score
(DNSMS)
Changes in DNSMS over time are shown in Figure 1.
DNSMS throughout the Japanese cedar pollen scat-
tering period were consistently lower in the omalizu-
mab group than in the placebo group.
The omalizumab group showed significantly lower
mean DNSMS compared to the placebo group during
the treatment period [LSM ± (SE), 1.391 ± 0.1769 for
the omalizumab group and 2.499±0.1740 for the pla-
cebo group; P < .001; Figure 2A]. Statistical analyses
revealed similar results with respect to the relevant
scores during the Japanese cedar pollen scattering
period (1.915 ± 0.2267 and 3.528 ± 0.2258, respec-
tively; P < .001; Figure 2A ) and the peak Japanese
cedar pollen scattering period (2.586 ± 0.2907 and
4.511 ± 0.2886, respectively; P<.001; Figure 2A ). Dur-
ing the Japanese cedar pollen scattering period, sub-
jects with lower mean DNSMS were distributed pre-
dominantly in the omalizumab group than in the pla-
cebo group, with greater numbers of subjects with
scores of 0―1 and >2―4 in the former and latter
groups, respectively . About half of subjects in the
omalizumab group had a mean DNSMS of2 (mild
or less severe symptoms) in contrast to 15% in the
placebo group. More than 10% of subjects in the pla-
cebo group had scores of >6 (severe symptoms) com-
pared to none in the omalizumab group (Fig. 2B).
As shown in Figure 1, the amount of Japanese ce-
dar pollen in Tokyo was larger than that of Osaka
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Fig. 1 Time-course changes in daily nasal symptom medication score (FAS) and in 
amount of Japanese cedar polen. Day 0 represents the start day of the Japanese cedar 
polen scatering period in Tokyo and Osaka.
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Table 1 Patient characteristics
Placebo (n＝50)Omalizumab (n＝48)
Gender
2825　Male
Age (years) 
31.5 ± 12.332.2 ± 12.1　Mean ± SD
20―6420―62　Range
History of SAR induced by Japanese cedar polens (years)
9.6 ± 5.411.3 ± 6.2 　Mean± SD
 3―26 4―35　Range
Specific IgE levels against Japanese cedar polens (CAP-RAST) ＊
 0 3　Class 2 (0.70―3.49 UA/mL)
1215　Class 3 (3.50―17.49 UA/mL)
2519　Class 4 (17.50―49.99 UA/mL)
 9 8　Class 5 (50.00―99.99 UA/mL)
 4 3　Class 6 (＞＿ 100 UA/mL)
Serum total IgE levels at baseline (IU/mL)
188.7 ± 145.8193.7 ± 166.6　Mean ± SD
 34.0 ± 570.0 32.0 ± 590.0　Range
＊: Specific IgE levels against Japanese cedar polens at baseline were categorized into 7 groups (Classes 0 to 6), and a ＞＿ 2 class 
group was assessed to be positive against the alergen.
(5648 grainscm2 for Tokyo and 913 grainscm2 for
Osaka). Although in the placebo group as well as in
the omalizumab group , the subgroup of Tokyo
showed higher mean DNSMS compared to that of
Osaka, the mean DNSMS were consistently lower in
the omalizumab group than in the placebo group in
Tokyo and Osaka, respectively [Mean ± (SE), 3.020 ±
0.2576 and 4.697 ± 0.3390 for Tokyo, 1.141 ± 0.2423
and 2.705 ± 0.2682 for Osaka, the Japanese cedar pol-
len scattering period]. Statistically, there was no in-
teraction between the treatment group and the region
( P = .8429).
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Fig. 2 A) Mean daily nasal symptom medication scores (DNSMS) and C) mean daily ocular symptom medication scores 
(DOSMS) during the treatment period, the Japanese cedar (JC) polen scatering period, and the peak JC polen scatering 
period. Percentages of the total of patients with B) mean DNSMS and D) mean DOSMS during the JC polen scatering period.
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Daily Nasal Rescue Medication Score
The mean daily nasal rescue medication scores were
significantly lower in the omalizumab group than in
the placebo group during the three evaluation peri-
ods (e.g., 0.055 ± 0.0503 and 0.260 ± 0.0499, respec-
tively; P = .002, the peak Japanese cedar pollen scat-
tering period).
Daily ocular symptom medication score
(DOSMS)
The omalizumab group had significantly lower mean
DOSMS compared to the placebo group during the
treatment period (0.458 ± 0.1248 and 1.245 ± 0.1227,
respectively; P < .001; Fig. 2C ). Statistical analyses
revealed similar results with respect to the relevant
scores during the Japanese cedar pollen scattering
period (0.654 ± 0.1675 and 1.766 ± 0.1688, respec-
tively; P < .001) and the peak Japanese cedar pollen
scattering period (1.007 ± 0.2244 and 2.468 ± 0.2228,
respectively; P<.001). During the Japanese cedar pol-
len scattering period, approximately 70% (3247) of
subjects in the omalizumab group had ocular symp-
tom medication scores of1 (Fig. 2D).
Daily Ocular Rescue Medication Score
The mean ocular rescue medication scores were sig-
nificantly lower in the omalizumab group than in the
placebo group during the three evaluation periods (e.
g., 0.031 ± 0.0360 and 0.191 ± 0.0357, respectively; P<
.001, the peak Japanese cedar pollen scattering pe-
riod).
Daily nasal and ocular symptom severity scores
(DNSS & DOSS)
The omalizumab group had significantly lower mean
DNSS compared to the placebo group during the
three evaluation periods (e .g . , 1.880 ± 0.2183 and
3.349 ± 0.2175, respectively; P < .001, the Japanese ce-
dar pollen scattering period ) . Each of the mean
DNSS and DOSS during the three evaluation periods
(sneezing, runny nose, stuffy nose, itchy nose, itchy
eyes, watery eyes, and red eyes) was significantly
lower in the omalizumab group ( P values ranging
from < .001 to .003; Fig. 3 ).
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Fig. 3 Efects of omalizumab on each of the mean daily nasal and ocular symptom sever-
ity scores (FAS) during the Japanese cedar polen scatering period (P ＜ .001 for al 
variables). Statisticaly significant diferences were noted during the treatment period and 
peak Japanese cedar polen scatering periods.
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Use of Rescue Medications
The mean consumption per day of each of the three
rescue medications [clemastine fumarate (tablet), so-
dium cromoglycate (nose drop, eye drop)] was sig-
nificantly lower in the omalizumab group than in the
placebo group during the three evaluation periods ( P
values ranging from .002 to .017), and naphazoline ni-
trate (nose drop) tended to show a significant differ-
ence in consumption . The proportions of days in
which any rescue medication was taken were almost
5-fold higher in the placebo group than in the omali-
zumab group (e.g., 25.4% and 5.6%, respectively; P <
.001, the peak Japanese cedar pollen scattering pe-
riod).
SERUM FREE IgE LEVELS
Serum free ( total ) IgE levels in the omalizumab
group and the placebo group at baseline were at simi-
lar levels ( Table 1 ). After administrations, serum
free IgE levels in the omalizumab group decreased
markedly, compared to the baseline levels to below
50 ngmL at 4 and 12 weeks of the treatment period
in all subjects (range from 6.1 ngmL to 39.6 ngmL).
In the placebo group , serum free IgE levels were
comparable to the baseline levels throughout the
treatment period (range from 39.7 ngmL to 1314
ngmL).
SAFETY
Treatment with omalizumab was generally well toler-
ated. Due to the higher overall incidence of injection
site reactions in the omalizumab group, the overall in-
cidences of drug-related adverse events were signifi-
cantly higher in the omalizumab group than in the
placebo group ; nevertheless , the adverse reaction
profile was similar between the study groups when
excluding injection site reactions ( Table 2 ). One se-
rious adverse event (colitis ulcerative) was reported
in one subject in the omalizumab group, who was
subsequently withdrawn from this study. However ,
the investigator considered its causality with the drug
unlikely. Another subject in the omalizumab group
and one subject in the placebo group discontinued
treatment because of non-serious adverse events
which were not drug-related. There were no anaphy-
lactic reactions , and neither evidence of immune
complex disease, nor clinically important abnormali-
ties in vital signs and laboratory tests were found. No
anti-omalizumab antibodies were detected.
DISCUSSION
This randomized , placebo-controlled , double-blind
study revealed that omalizumab was generally well
tolerated and was effective in preventing and control-
ling rhinoconjunctival symptoms associated with
Japanese cedar pollen-induced SAR and in reducing
rescue medication use for rhinoconjunctival symp-
toms.
Although the amount of Japanese cedar pollen in
Tokyo was larger than that of Osaka , the mean
DNSMS were consistently lower in the omalizumab
group than in the placebo group in Tokyo and Osaka,
respectively. Statistically, there was no interaction be-
tween the treatment group and the region. Taken to-
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Table 2 Drug-related adverse events
Placebo (n＝50)Omalizumab (n＝48)
10 (20.0)19 (39.6)Total number of patients with ADR ＊
1 (2.0)1 (2.1)Gastrointestinal disorders
01 (2.1)　Colitis ulcerative 
1 (2.0)0　Diarhea
 5 (10.0)13 (27.1)General disorders and administration site conditions
2 (4.0) 7 (14.6)Erythema　Injection site ＊
1 (2.0)1 (2.1)Induration
1 (2.0) 8 (16.7)Edema
1 (2.0)2 (4.2)Pain
02 (4.2)Pruritus
01 (2.1)　Feeling hot
1 (2.0)0　Fatigue
01 (2.1)　Pain
1 (2.0)0　Fever
2 (4.0)0Nervous system disorders
2 (4.0)0　Headache
2 (4.0)1 (2.1)Skin and subcutaneous tissue disorders
01 (2.1)　Dry skin
1 (2.0)0　Rash
1 (2.0)0　Face edema (lip sweling)
   4 (8.0)＃2   4 (8.3)＃1Investigations
＊: P＜.05;↑: increased;↓: decreased
＃1: Bilirubin↑(1), neutrophil↓(1), WBC↓(1), WBC↑(2)
＃2: GPT↑(1), eosinophil↑(2), lymphocyte↓(1), WBC↑(1)
gether, regardless of the amount of Japanese cedar
pollens, omalizumab would be more effective against
SAR.
Our results indicate that subjects treated with
omalizumab not only had significantly less severe na-
sal and ocular symptoms, but also required signifi-
cantly less rescue medication compared to subjects
receiving placebo . In addition , we conducted a
double-blind controlled studyusing a competing anti-
allergy drug in the next Japanese cedar pollen scat-
tering period, i.e., from February to April 2003. The
results showed that omalizumab had significantly
lower nasal symptoms and consumption of rescue
medications than the competitor (data not shown).
Our results suggest that monotherapy with omalizu-
mab at a 2- or 4-week interval can control both nasal
and ocular symptoms, thus simplifying SAR therapy.
The omalizumab regimen in the present study was
considered appropriate also for Japanese patients
with SAR because the regimen successfully de-
creased serum free IgE levels to below 50 ngmL,
providing proper clinical efficacy, in contrast to the
results obtained in foreign studies.
In the omalizumab group, all adverse events except
for one (colitis ulcerative) were mild or moderate in
severity. The most frequently observed drug-related
adverse event in the omalizumab group and the pla-
cebo group were injection site reactions, with a sig-
nificantly higher overall incidence in the former; how-
ever, the adverse reaction profile was similar between
the two groups when excluding the incidences of in-
jection site reactions. No clinically important abnor-
mal values in laboratory tests or vital signs were re-
ported; no anti-omalizumab antibodies were detected.
Furthermore, no cases of anaphylaxis were reported.
Therefore , the safety profile of omalizumab in the
treatment of SAR seems favorable.
To determine whether omalizumab could consis-
tently provide safety and efficacy in the subsequent
season, we conducted an open-label study in the next
Japanese cedar pollen scattering period, i .e . , from
February to April 2003, in order to administer omali-
zumab to the same subjects who had received the
drug in the present study. Consequently, the open-
label study revealed no serious adverse events at all
and was comparable to the present study with respect
to both efficacy and safety (data not shown).
The site of action of omalizumab is localized in free
IgE in the circulation, probably local tissues. Omali-
zumab forms small biologically inert immunocom-
plexes with free IgE and blocks the interaction be-
tween IgE and FcεR which is expressed on the sur-
face of target cells. Additionally, decreases in free IgE
levels in microenvironments around mast cells and
dendritic cells have been proven to induce the down-
regulation of FcεRI expression on the cell surface;9,21
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the relevant down-regulation is noteworthy because it
provides a clinical benefit of possibly reducing the re-
activity of mast cells. B lymphocyte apoptosis, the in-
hibition of IgE production by B lymphocytes,22,23 and
the inhibition of Th2 cytokine production24 may also
be induced by omalizumab treatment. A significant
decrease in serum free-IgE levels induced by omali-
zumab only resembles the transient knockout of IgE
because it recovers in a few months after the comple-
tion of administration . 12 Considered comprehen-
sively, omalizumab may be potentially beneficial for
SAR patients in the clinical settings because it strate-
gically targets sites upstream from the allergic reac-
tion cascade.
Other studies have shown the efficacy of omalizu-
mab for SAR induced by ragweed or birch pol-
lens. 12-14 Recently , its efficacy in perennial allergic
rhinitis (PAR)15 has also been reported. Thus, omali-
zumab has also clinically been proven to be effective
for allergic rhinitis regardless of allergen type and
clinical entity. Furthermore, omalizumab induces a
non-anaphylactogenic condition, and its combination
with specific immunotherapy effectively suppresses
enhanced immune responsiveness of patients to a
particular allergen and also enhances the efficacy of
specific immunotherapy.25
In conclusion, omalizumab was well tolerated and
effective in preventing and controlling symptoms and
in reducing rescue medication use in patients with
moderate-to-severe Japanese cedar pollen-induced
SAR. Therefore, omalizumab represents a new prom-
ising therapeutic modality for patients with SAR in-
duced by Japanese cedar pollens.
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